Edition:
India

CHF Solutions Inc (CHFS.OQ)

CHFS.OQ on NASDAQ Stock Exchange Capital Market

4.35USD
22 Nov 2017
Change (% chg)

$-3.53 (-44.80%)
Prev Close
$7.88
Open
$4.80
Day's High
$4.90
Day's Low
$4.26
Volume
751,433
Avg. Vol
59,662
52-wk High
$576.00
52-wk Low
$3.61

Summary

Name Age Since Current Position

John Erb

68 2016 Chairman of the Board, President, Chief Executive Officer

Claudia Drayton

49 2015 Chief Financial Officer, Secretary

Gordon Weber

2017 Vice President, General Counsel

Steven Brandt

57 2017 Director

Matthew Likens

64 2017 Director

Jon Salveson

52 2013 Independent Director

Gregory Waller

67 2011 Independent Director

Warren Watson

65 2013 Independent Director

Biographies

Name Description

John Erb

Mr. John L. Erb is Chairman of the Board, President, Chief Executive Officer of the Board of the Company. John L. Erb currently serves as chief executive officer and president and has served as a director of the Company since September 2012 and as Chairman of the Board since October 2012. He is currently chief executive officer of NuAx, Inc. (formerly Cardia Access, Inc.), a medical device company involved in developing new devices for the treatment of heart disease, a position he has held since February 2007. Previously, Mr. Erb served as executive chairman of the board (during 2007) and as chief executive officer (from 2001 to 2006) of CHF Solutions, Inc., a medical device company involved in the development, manufacturing and distribution of devices to treat congestive heart failure; as president and chief executive officer of IntraTherapeutics, Inc., a medical device company involved in the development, manufacturing and distribution of peripheral vascular stents, from 1997 to 2001; and in various positions, including vice president of worldwide operations, at Schneider, a division of Pfizer, Inc., from 1991 to 1997. Mr. Erb’s prior board experience includes service as a director of SenoRx, Inc., a publicly traded company, from December 2001 to July 2010, service as a director of CryoCath Technologies Inc., a publicly traded Canadian company, from October 2000 to December 2008, and service as director of Vascular Solutions, Inc. (a Nasdaq listed company) from 2002 to February 2017. While on the board of Vascular Solutions, Mr. Erb served as Chairman of the Board of Directors, chairman of the compensation committee, and of the nominating and corporate governance committees. Mr. Erb currently serves as a director of NuAx, as well as Osprey Medical, Inc. (listed on the Australian Securities Exchange; serves as chairman of the compensation committee and a member of the audit committee), Mr. Erb received a B.A. degree in business administration, with a concentration in finance from California State University,

Claudia Drayton

Ms. Claudia Drayton is Chief Financial Officer, Secretary of CHF Solutions Inc. Claudia Drayton has served as our Chief Financial Officer and Secretary since January 2015. Prior to joining the Company, Ms. Drayton spent 15 years at Medtronic, Inc., a $17 billion global leader in the medical device industry. During her tenure at Medtronic, Ms. Drayton held multiple senior managerial finance positions, culminating with an assignment in Europe serving as chief financial officer of the peripheral vascular business (2010-2012) and most recently, as chief financial person and senior finance director of the integrated health solutions business (2012-2014). In these capacities, her responsibilities and experiences included profitability management, strategic planning, mergers and acquisitions, planning and forecasting, and implementation of financial best practices. Before joining Medtronic, Ms. Drayton was an audit and business advisory manager at Arthur Andersen for seven years. Ms. Drayton holds an MBA from the University of Minnesota’s Carlson School of Management, a BS from the University of Mary Hardin-Baylor and is a Certified Public Accountant (inactive).

Gordon Weber

Mr. Gordon Weber is Vice President, General Counsel of the company. Prior to joining Sunshine Heart, Mr. Weber was Vice President, General Counsel and Corporate Secretary for Vascular Solutions, Inc., a publicly held medical device company, was Associate General Counsel at Smiths Medical, a $1.1B medical device manufacturer, and was a partner at Faegre & Benson LLP. Mr. Weber holds a J.D. from William Mitchell College of Law, and a B.A. in Accounting and Economics from Luther College.

Steven Brandt

Mr. Steven F. Brandt is Director of the Company. He has served as a director of the Company since February 2017. Mr. Brandt is a senior executive with over 35 years of experience in the healthcare industry. Mr. Brandt was employed by Thoratec Corporation from November 2004 to October 2015, serving as Vice President Global Sales and Marketing, Vice President of Global Sales and Vice President International Sales. Prior to Thoratec, Mr. Brandt was Vice President Sales & Marketing for CHF Solutions from October 2002 to November 2004 and Vice President Global Marketing, Cardiovascular Surgery Division for St. Jude Medical from November 2000 to October 2002. Mr. Brandt received his B.S. from Franklin Pierce College.

Matthew Likens

Mr. Matthew E. Likens is Director of the Company. Matthew E. Likens has served as a director of the Company since February 2017. Mr. Likens is a principal at Likens Healthcare and Management Consulting, LLC. He was the President and CEO of Ulthera, Inc. from 2006 to 2016. Prior to Ulthera, Mr. Likens was employed at GMP Companies, Inc. as President of GMP Wireless Medicine from 2001 to 2006 and Executive Vice President, Operations from 2001 to 2004. Mr. Likens previously served in various capacities at Baxter Healthcare Corporation from 1978 to 2001, and was President of Baxter’s Renal U.S. business upon his departure in January, 2001. Mr. Likens has a B.B.A. in Marketing from Kent State University. Mr. Liken’s qualifications to serve on the Board include his years of management experience, including his experiences as president and chief executive officer of Ulthera, Inc.

Jon Salveson

Mr. Jon W. Salveson is an Independent Director of the Company. Jon W. Salveson has served as a director of the Company since March 2013. Mr. Salveson is vice chairman, investment banking and chairman of the healthcare investment banking group at Piper Jaffray Companies. He also serves on the board of CryoLife, Inc. (NYSE: CRY), a leading medical device company focused on cardiac and vascular surgery. Mr. Salveson joined Piper Jaffray in 1993 as an associate, was elected managing director in 1999, and was named group head of Piper Jaffray’s international healthcare investment banking group in 2001. Mr. Salveson was appointed global head of investment banking and a member of the executive committee of Piper Jaffray in 2004, and has served in his present position as vice chairman, investment banking since July 2010. Mr. Salveson started his career as a market manager at Bio-Metrics Systems (now part of Surmodics, Inc.), an innovator in medical device surface modification, where he gained experience working in cardiology and interventional medicine. Mr. Salveson’s qualifications to serve on the Board include his 20-plus years of experience in healthcare investment banking, advising clients on hundreds of merger and acquisition and financing transactions.

Gregory Waller

Mr. Gregory D. Waller is an Independent Director of the Company. He has served as a director of the Company since August 2011. Mr. Waller also serves on the board of Endologix Corporation, a publicly traded company (currently, chairman of the audit committee and a member of the nominating and governance committee), and until April 2015 was chief financial officer of Ulthera, Inc., a privately held company that sells an ultrasound device used for non-invasive brow lifts, which was sold to Merz North America in July 2014. From March 2006 to April 2011, Mr. Waller was chief financial officer of Universal Building Products, Inc., a manufacturer of concrete construction accessories. Mr. Waller served as vice president of finance, chief financial officer, and treasurer of Sybron Dental Specialties, Inc., a manufacturer and marketer of consumable dental products, from August 1993 until his retirement in May 2005, and was formerly vice president and treasurer of Kerr, Ormco Corporation, and Metrex. Mr. Waller joined Ormco in December 1980 as vice president and controller and served as vice president of Kerr European Operations from July 1989 to August 1993. Mr. Waller has an M.B.A. with a concentration in accounting from California State University, Fullerton. Mr. Waller’s qualifications to serve on the Board include his 44 years of financial and management experience, including his experiences as chief financial officer of Universal Building Products, Sybron Dental Specialties and Ulthera, Inc., as well as his familiarity with public company board functions from his service on the boards of other public companies. As described above, Mr. Waller served as chief financial officer of Universal Building Products from 2006 to 2011. Universal Building Products filed a voluntary petition for bankruptcy on August 4, 2010. Except as described in the preceding sentence, no other event has occurred during the past 10 years requiring disclosure pursuant to Item 401(f) of Regulation S-K.

Warren Watson

Mr. Warren S. Watson is an Independent Director of the Company. Warren S. Watson has served as a director of Sunshine Heart since January 2013. Mr. Watson is an executive with over 40 years of experience in the field of medical devices. From 1982 to 2014, Mr. Watson served on the board of directors of Citizens Independent Bank of St. Louis Park, Minnesota, a community bank with four branches and $300 million in assets. From 2010 to 2012, he served as executive chairman of Cameron Health Inc., a medical technology company focused on subcutaneous implantable cardioverter and defibrillator devices. From 2004 to 2009, Mr. Watson served as a director for CardioMems, Inc., a start-up company focused on pulmonary artery pressure monitoring for patients with heart failure. From 2002 to 2009, Mr. Watson served as vice president of Cardiac Rhythm Management Research and Development, an organization leading over 1,800 professionals worldwide; he also served as chair of the Medtronic Corporate Research and Development Council during his tenure with that organization. From 2002 to 2007, Mr. Watson served as vice president and general manager of the San Jose-based CardioRhythm cardiac ablation business. Mr. Watson’s qualifications to serve on the Board include his executive leadership in the field of medical devices, his 40 years of experience in the medical technology field, his successful development of multiple emerging therapies and his general business experience due to his board service for other medical technology companies such as Mardil, Inc. (2013-2016), Cardialen, Inc. (since 2012), NuAx (since 2011) and Closys (2013-2016).

Basic Compensation

Name Fiscal Year Total

John Erb

1,214,100

Claudia Drayton

410,805

Gordon Weber

--

Steven Brandt

--

Matthew Likens

--

Jon Salveson

--

Gregory Waller

--

Warren Watson

--
As Of  31 Dec 2016